As the warm winter effect continues into the spring of 2026, pollen seasons have started significantly earlier across many parts of the country, heralding a new wave of symptom peaks for China's 250 million allergic rhinitis patients. Against this backdrop, GRAND PHARMA's globally innovative compound nasal spray for allergic rhinitis, known as Laite Ling® (Olopatadine Mometasone Nasal Spray), has been launched, providing a new treatment option for a vast number of patients. Recently, the domestic launch ceremony for Laite Ling® was held simultaneously in six Chinese cities: Wuhan, Beijing, Shanghai, Guangzhou, Chongqing, and Nanjing. The event brought together top domestic and international experts in otorhinolaryngology and allergology to witness the official introduction of this innovative compound nasal spray in China.
Laite Ling® is primarily indicated for the treatment of allergic rhinitis in adults and children. Its launch fills a clinical gap for compound formulations for allergic rhinitis in children aged six and above in China, offering a world-leading treatment solution for nearly 250 million patients. This also marks a significant addition to GRAND PHARMA's portfolio in the upper airway chronic disease treatment sector. The introduction of this core product further strengthens the company's comprehensive competitiveness in the respiratory and critical care segment, ushering in a new era of compound therapy for rhinitis treatment in China.
Addressing the urgent needs of 250 million patients, this innovative compound formulation fills multiple clinical gaps. As a mature innovative drug already approved in multiple countries and regions globally, Laite Ling® is supported by extensive clinical data. Results from its Phase III clinical study showed that the product's efficacy was significantly superior to two original single-agent positive control drugs, with safety, tolerability, and pharmacokinetic profiles all meeting pre-set clinical endpoints, fully demonstrating its robust clinical value.
As a compound preparation, Laite Ling® offers unparalleled advantages over existing single-agent formulations. The product innovatively combines olopatadine and mometasone furoate. This treatment approach, which combines a nasal antihistamine with a nasal corticosteroid, is recommended as a first-choice option in the 2022 Chinese Guidelines for the Diagnosis and Treatment of Allergic Rhinitis. Currently, the domestic market is predominantly served by single-agent formulations, with a scarcity of compound options, particularly for patients aged six and above, leaving a significant gap. Many patients face limitations in treatment effectiveness and the inconvenience of combination therapy. Laite Ling® addresses this clinical need by providing a one-stop solution for domestic allergic rhinitis patients, especially those over six years old, significantly improving medication adherence.
During the academic discussion segment of the launch event, authoritative experts including Professor Zhang Luo from Capital Medical University, Professor Claus Bachert of the German Academy of Sciences, and Professor Wang Xiangdong highlighted that the launch of Laite Ling® represents a breakthrough choice for AR management, enabling a "dual-track" treatment approach. The large population of allergic rhinitis patients in China gives Laite Ling® clear clinical value. As a highly prevalent chronic respiratory disease in China, the prevalence rate of allergic rhinitis had already reached 20.9% in 2019, with a rate of 18.46% among children and adolescents, totaling nearly 250 million patients. Furthermore, the prevalence rate continues to rise steadily; it is projected that the number of allergic rhinitis patients in China will grow to 1.497 billion by 2033.
Given this vast patient population, China's allergic rhinitis drug market has long surpassed the tens of billions of RMB mark and is expected to continue growing. According to data from Head leopard Research, the market size for allergic rhinitis medications in China is projected to grow from RMB 43.275 billion in 2024 to RMB 50.09 billion in 2028, representing a compound annual growth rate of approximately 3.72%.
Targeting this disease market with significant potential, GRAND PHARMA has established a diversified product matrix that covers patients with mild, moderate, and severe symptoms and caters to different age groups, creating a competitive advantage that is difficult to replicate. In the field of allergic rhinitis treatment, GRAND PHARMA not possesses the globally innovative compound nasal spray Laite Ling®, but has also pipeline including several high-potential products. Among them, Fluticasone Propionate Nasal Spray and Budesonide Nasal Spray have been launched as the first generic versions in China, while the registration process for Mometasone Furoate Nasal Spray is steadily advancing.
GRAND PHARMA is currently actively preparing for the national innovative drug医保 negotiation for Laite Ling®. With future successful inclusion in the national reimbursement drug list, the clinical accessibility of the product is expected to be further enhanced, covering a broader patient base. Considering the domestic patient population of nearly 250 million and the multi-billion-yuan rhinitis medication market, Laite Ling® possesses strong potential for significant market uptake and has the potential to become a blockbuster product in the rhinitis treatment sector. This will further increase the company's market share in the rhinitis medication market, solidifying its position as a key player in the domestic allergic rhinitis treatment field and injecting strong, sustained momentum into the company's performance growth.
Strengthening the Core Respiratory and Critical Care Portfolio; STC3141 Unlocks Multi-Billion Dollar Market Potential. The launch of Laite Ling® is not only a significant breakthrough for GRAND PHARMA in the allergic rhinitis segment but also another milestone in the company's deep cultivation of its core strategic area of respiratory and critical care diseases. As one of the company's key business segments, GRAND PHARMA has been dedicated to the respiratory disease treatment field for many years, forming a relatively comprehensive product portfolio. Its marketed products widely cover multiple indications including rhinitis, bronchitis, pneumonia, asthma, and chronic obstructive pulmonary disease, laying a solid foundation for the segment's continuous growth.
Specifically, two of the company's global innovative compound formulations for asthma treatment, Enzhuorun® Bisscholer® and Enmingrun® Bisscholer®, have been included in the National Reimbursement Drug List and are currently in a phase of rapid sales expansion, serving as important growth engines for the respiratory segment. The exclusive product Qinuo, explicitly recommended by multiple clinical guidelines and expert consensus, holds a leading position in the market for acute and chronic sinusitis and respiratory diseases, with annual sales exceeding RMB 1 billion.
Beyond its rich portfolio of marketed products, GRAND PHARMA is deeply engaged in innovative R&D targeting unmet major clinical needs within the respiratory and critical care field, building a clearly stratified pipeline with immense potential. The pipeline covers refractory diseases such as sepsis and Acute Respiratory Distress Syndrome (ARDS). Among these, the globally first-in-class drug STC3141 stands as a core benchmark for the segment and the company's innovation efforts, possessing the potential to access a global market worth tens of billions of dollars.
Sepsis is one of the most common causes of death in intensive care units worldwide, claiming over 10 million lives annually. Clinical treatment has long relied mainly on symptomatic management, lacking specific drugs targeting the core pathophysiology, creating an extremely urgent global clinical need. Treatment costs for this condition in the US alone are projected to exceed $38 billion by 2027, while annual related treatment costs in China also amount to hundreds of billions of RMB.
STC3141, as the world's first sepsis treatment focusing on reconstituting immune homeostasis,颠覆s the traditional symptomatic treatment approach. It precisely modulates the core pathophysiology of immune dysregulation. The Phase II clinical study conducted in China for treating sepsis has successfully met its primary endpoints, validating the product's excellent performance in efficacy, safety, and tolerability. Furthermore, it showed positive signals in key efficacy indicators such as helping patients wean off ventilators, discontinue vasopressors, and shorten ICU stays. Currently, the product has obtained seven clinical trial approvals across five countries on three continents: China, Australia, Belgium, the UK, and Poland. All four completed patient clinical studies have successfully met their endpoints, and clinical studies for conditions like ARDS are progressing steadily, continuously expanding the potential indications.
The formal commercial launch of Laite Ling® in China further enhances GRAND PHARMA's product layout in the respiratory field, making the product matrix within the respiratory and critical care segment more synergistic and competitive. The company stated that, moving forward, it will remain patient-centric, increase investment in global innovative products and advanced technologies to address unmet clinical needs, and build a comprehensive product cluster for the full-cycle management of airway chronic diseases, aiming to contribute further to the advancement of airway disease treatment in China.
Comments